PLA-Inhibitors (stoPLA): New class of NSAIDs for oral and transdermal pain treatment
Phospholipase A2 (PLA2) designates a large and diverse
group of enzymes that cleave phospholipids at the sn-2- position. This metabolic step is instrumental in a variety of pathogenic processes causing pain, fever and inflammation. Presently glucocortidoids are used for inhibition of PLA2. Unfortunately, glucocortidoids have serious side effects which limit their use as medication for pain treatment. stoPLA is a new class of heteroaryl-substituted acetone derivatives for the effective inhibition of PLA2, especially of cytosolic PLA2. These compounds effectively interact with the synthesis of prostaglandins and leukotrienes and reduce inflammatory processes. The new heteroarylsubstituted acetone derivatives have also an excellent solubility profile and are stable against metabolic inactivation through ketogroup reduction.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Better magnets for green energy
Researchers use multicomponent alloys to make strong and ductile soft magnetic materials. Latest results now published in the journal Nature. Soft magnetic materials (SMMs) applied in electric engines transform energy…
Sound plus electrical body stimulation has potential to treat chronic pain
New technique could relieve pain for individuals with various chronic and neurological conditions. A University of Minnesota Twin Cities-led team has found that electrical stimulation of the body combined with…
Bioengineered cornea can restore sight to the blind and visually impaired
Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts. Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which…
